Nanjing, China., Sept 1, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will give an oral presentation with title 'Clinical Responses and Pharmacokinetics of fully human BCMA Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma' (abstract # 440) at 17th International Myeloma Workshop in Boston, MA. on Sept 12-15.
For more information, please visit:http://imw2019boston.org/index.php/program/friday-september-13
